APRI: A simple bedside marker for advanced fibrosis that can avoid liver biopsy in patients with NAFLD/NASH

South African Medical Journal

Volumn 101, Issue 7, 2011, Pages 477-480

  Kruger, Frederik Cornelis ^a   Daniels, Caroline Rachel ^a   Kidd, Martin ^b   Swart, Gillaum ^c   Brundyn, Karen ^c   van Rensburg, Christo ^c   Kotze, Maritha ^c  

^a Durbanville Medi Clinic   (South Africa)

^b STELLENBOSCH UNIVERSITY   (South Africa)

^c UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALCOHOLIC FATTY LIVER; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE TO ALANINE AMINOTRANSFERASE RATIO; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; CLINICAL PRACTICE; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE MARKER; DISEASE SEVERITY; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; LIVER BIOPSY; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NON INVASIVE MEASUREMENT; NONALCOHOLIC FATTY LIVER; NONALCOHOLIC STEATOHEPATITIS FIBROSIS SCORE; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; REFERENCE VALUE; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; THROMBOCYTE; VALIDATION STUDY;

ASPARTATE AMINOTRANSFERASES; FATTY LIVER; FEMALE; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PLATELET COUNT; POINT-OF-CARE SYSTEMS; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY;

EID: 79960979728     PISSN: 02569574     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology 2004;40:1387-1395.
2. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for nonalcoholic fatty liver disease: Te Dionysos nutrition and liver study. Hepatology 2005;42:42-52.
3. Fan JG, Zhu J, Li XJ, et al. Prevalence of and risk factors for fatty liver in the general population of Shanghai, China. J Hepatol 2005;43:508-514.
4. Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: Present and future. Hepatology 2007;46(2):582-589.
5. Matteoni CA, Younossi ZM, Gramlich T, Boparai N, Liu YC, McCullough AJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413-1419.
6. Bugianessi E, Leone N, Vanni E, et al. Expanding the natural history of non-alcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-140.
7. Ratziu V, Charlotte F, Heurtier A, et al. Sampling variability of liver biopsy in non-alcoholic fatty liver disease. Gastroenterology 2005;128:1898-1906.
8. Adams LA, Lymp JF, St Sauver J, et al. Te natural history of non-alcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-121.
9. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865-873.
10. Kruger FC, Daniels C, Swart G, Van Rensburg CJ, Kidd M, Hall P. Correlation of body mass index (BMI) with the diferent types of nonalcoholic fatty liver disease (NAFLD). S Afr Med J 2004;8:682 (abstract).
11. McGill DB, Rakela J, Zinmeister AR, et al. A 21 yr experience with major hemorrhage afer percutaneous liver biopsy. Gastroenterology 1990;99:1396.
12. Mofrad P, Contos MJ, Hague M, et al. Clinical and histological spectrum of non-alcoholic fatty liver disease associated with normal ALT values. Hepatology 2003;37:1286-1292.
13. Ruhl CE, Everhart JE. Determinants of the association of overweight with elevated serum alanine aminotransferase activity in the United States. Gastroenterology 2003;124:71-79.
14. Garcia-Monson C, Martin-Perez E, Iacono OL, et al. Characterization of pathogenic and prognostic factors of non-alcoholic steatohepatitis associated with obesity. J Hepatol 2003;33:716-724.
15. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of non-alcoholic steatohepatitis and liver fbrosis in the severely obese. Gastroenterology 2001;121:91-100.
16. Rockey DC, Bissel DM. Noninvasive measures of liver fbrosis. Hepatology 2006;43:S113-S120.
17. Ratzui V, Massard J, Charlotte F, et al. Diagnostic value of biochemical markers(Fibro Test- Fibro SURE) for the prediction of liver fbrosis in patients with nonalcoholic fatty liver disease. BMC Gastroenterol 2006;6:6.
18. Rosenberg WM, Voelker M, Tiel R, et al. Serum markers detect the presence of liver fbrosis: a cohort study. Gastroenterology 2004;127:1704-1713.
19. Angulo P, Hui, JM, Marchesini G, et al. Te NAFLD fbrosis score: a non-invasive system that identifes liver fbrosis in patients with NAFLD. Hepatology 2007;45:846-854.
20. Guha IN, Parkers J, Roderick P, et al. Non-invasive markers of fbrosis in non-alcoholic fatty liver disease: Validating the European liver fbrosis panel and exploring simple markers. Hepatology 2008;47:455-460.
21. Wai C T, Greenson JK, Fontana RJ, et al. A simple noninvasive index can predict both signifcant fbrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38:518-526.
22. Bianchi L. Liver biopsy in elevated liver functions tests? An old question revisited. J Hepatol 2001;35:290-294.
23. Adams LA, Sanderson SO, Lindor KD, et al. Te histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol 2005;42:132-138.